Long Term Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension

NCT01237873 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

Essential Hypertension

Interventions

DRUG: Ali/Amlo 150/2.5 mg

Sponsor

Novartis Pharmaceuticals